GLP-1RA and the possible skin aging.
Paschou IA., Sali E., Paschou SA., Tsamis KI., Peppa M., Psaltopoulou T.
Narrative Review on Type 2 Diabetes, Skin Aging, published in Endocrine (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Endocrine (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40498168
- PMCID
- PMC12370548
- DOI
- 10.1007/s12020-025-04293-w
- Citations
- 3
Abstract (original English)
"Ozempic face" and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic inflammation and possibly promote skin health. The rapid weight loss observed with GLP-1RA has been implicated in facial aging. However, recent evidence suggests further pathophysiological mechanisms for this side effect. The aim of this article is to review the literature and present available data on the possible mechanisms of GLP-1RA on skin aging. Indeed, GLP-1RA may affect other types of skin cells, which may accelerate the process of skin aging itself. More specifically, GLP-1RA can act on adipose-derived stem cells (ADSC) and fibroblasts, that present GLP-1R on their surface. Stimulation of the receptor reduces the ability of ADSC to produce protective cytokines. The absence of those cytokines promotes the production of reactive oxygen species (ROS) and causes oxidative damage on fibroblasts. GLP-1RA also reduce the glucose intake of the ADSC, leading to reduced production of ATP and apoptosis. Finally, the stimulation of GLP-1R on ADSCs reduces indirectly the production of estrogens from dermal white adipose tissues (DWAT), which reduces stimulation of fibroblasts to produce collagen. GLP-1RA can also affect the process of skin
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol